“If you're going to try to embrace new worlds, you must try to embrace new ideas."

genetic heart diseases

genetic heart diseases

genetic heart diseases

genetic heart diseases

SEO related. Do not remove this box.
Phlox Therapeutics pioneers gene therapy to alleviate and cure different heart diseases. By embracing new ideas, we want to change the world for patients to whom the current standard of care falls short. Current treatment often barely addresses symptoms and cannot halt the progression of the disease as it fails to target the underlying causes. Imagine the possibilities of our approach. We envision a world where our technology can cure genetic heart diseases, providing lifelong benefit to patients and their relatives. 
Cardiac dysfunction is the leading cause of death world-wide. Our ultimate goal is to cure genetic heart disease. Therefore, we develop a new class of potent precision genetic medicines. 

Latest news

Phlox Therapeutics closes seed investment round

Company’s technology set to revolutionize the treatment of genetic cardiovascular diseases through its development of RNA-based therapeutics May 2020, Naarden, The Netherlands – Phlox Therapeutics, a biotech spin-off of the Amsterdam University Medical Center founded by prof. dr. Yigal Pinto and prof. dr. Eva van Rooij, with Margien Boels, PhD as it’s initiating director of operations […]
continue reading

Founded

March 7th, 2022 – On the basis of more than 15 years of scientific efforts in the lab of Yigal Pinto, he, Eva van Rooij and Margien Boels have now officially founded Phlox Therapeutics B.V. as an Amsterdam UMC spin-off, funded by the FIRST fund. The name and logo of Phlox resembles the approach that […]
continue reading

Investors

logo image of F1RST Biogeneration Ventures

Team

profile picture of Prof. Dr. Yigal Pinto, part of Phlox Therapeutics

Prof. dr. Yigal Pinto

Founder and CMO
profile picture of Margien Boels, part of Phlox Therapeutics

Margien Boels 

Director of Operations
profile picture of Prof. Dr. Eva de Rooij, part of Phlox Therapeutics

Prof. dr. Eva Van Rooij

Founder and CSO

“If you're going to try to embrace new worlds, you must try to embrace new ideas."

Phlox Therapeutics pioneers gene therapy to alleviate and cure different heart diseases. By embracing new ideas, we want to change the world for patients to whom the current standard of care falls short. Current treatment often barely addresses symptoms and cannot halt the progression of the disease as it fails to target the underlying causes. Imagine the possibilities of our approach. We envision a world where our technology can cure genetic heart diseases, providing lifelong benefit to patients and their relatives. 

Cardiac dysfunction is the leading cause of death world-wide. Our ultimate goal is to cure genetic heart disease. Therefore, we develop a new class of potent precision genetic medicines.

Latest news

Phlox Therapeutics closes seed investment round

Company’s technology set to revolutionize the treatment of genetic cardiovascular diseases through its development of RNA-based therapeutics May 2020, Naarden, The Netherlands – Phlox Therapeutics, a biotech spin-off of the Amsterdam University Medical Center founded by prof. dr. Yigal Pinto and prof. dr. Eva van Rooij, with Margien Boels, PhD as it’s initiating director of operations […]
continue reading

Founded

March 7th, 2022 – On the basis of more than 15 years of scientific efforts in the lab of Yigal Pinto, he, Eva van Rooij and Margien Boels have now officially founded Phlox Therapeutics B.V. as an Amsterdam UMC spin-off, funded by the FIRST fund. The name and logo of Phlox resembles the approach that […]
continue reading

Investors

logo image of F1RST Biogeneration Ventures

Team

profile picture of Prof. Dr. Yigal Pinto, part of Phlox Therapeutics
Prof. dr. Yigal Pinto
Founder and CMO
profile picture of Margien Boels, part of Phlox Therapeutics
Margien Boels
Director of Operations
profile picture of Prof. Dr. Eva de Rooij, part of Phlox Therapeutics
Prof. dr. Eva Van Rooij
Founder and CSO